Opus Genetics Confirms FDA Alignment On Phase 3 Study Design To Evaluate OPGx-LCA5

July 06, 2026 — 07:30 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Opus Genetics (IRD) has reached alignment with the FDA in a Type B Rare Disease Evidence Principles meeting on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated inherited retinal disease. The company has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The FDA indicated that Opus Genetics may submit a Biologics License Application based on efficacy at the six-month primary endpoint, with 12-month durability data submitted during the BLA review process.

The Phase 3 study is expected to enroll eight participants. Seven of the eight planned participants have already been enrolled and are currently completing the run-in period, and the company expects to initiate dosing in the fourth quarter of 2026.

In pre-market trading on NasdaqCM, Opus Genetics shares are up 2.55 percent to $4.3378.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Opus Genetics Confirms FDA Alignment On Phase 3 Study Design To Evaluate OPGx-LCA5

Tags

Latest Articles